Scleroderma laboratory findings: Difference between revisions
Jump to navigation
Jump to search
m (Categories) |
m (Bot: Removing from Primary care) |
||
| (8 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Scleroderma}} | {{Scleroderma}} | ||
{{CMG}} | |||
{{CMG}}; {{AE}} {{MKA}} | |||
==Overview== | ==Overview== | ||
Specific laboratory findings consistent with the diagnosis of scleroderma include: Anti-Scl-70 [[antibody]] ([[Topoisomerase I]]), anti-centromere [[antibody]] ([[CREST syndrome]]), [[Anti-nuclear antibody|anti-nuclear antibody (ANA)]], anti-RNA polymerase III [[antibody]], anti-U1-RNP [[antibody]]. | |||
==Laboratory Findings== | ==Laboratory Findings== | ||
Laboratory findings consistent with the diagnosis of scleroderma include:<ref name="pmid6155920">{{cite journal |vauthors=Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C |title=Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome |journal=Arthritis Rheum. |volume=23 |issue=6 |pages=617–25 |date=June 1980 |pmid=6155920 |doi= |url=}}</ref> | |||
*Anti-Scl-70 [[antibody]] ([[Topoisomerase I]]) | |||
*Anti-centromere [[antibody]] ([[CREST syndrome]])<ref name="pmid6384675">{{cite journal |vauthors=Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL |title=The anticentromere antibody: disease specificity and clinical significance |journal=Mayo Clin. Proc. |volume=59 |issue=10 |pages=700–6 |date=October 1984 |pmid=6384675 |doi= |url=}}</ref> | |||
*[[Anti-nuclear antibody|Anti-nuclear antibody (ANA)]] | |||
*Anti-RNA polymerase III [[antibody]] | |||
*Anti-U1-RNP [[antibody]] | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Up-To-Date]] | |||
[[Category:Medicine]] | |||
[[Category:Dermatology]] | |||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
Latest revision as of 00:05, 30 July 2020
|
Scleroderma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Scleroderma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Scleroderma laboratory findings |
|
Risk calculators and risk factors for Scleroderma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
Specific laboratory findings consistent with the diagnosis of scleroderma include: Anti-Scl-70 antibody (Topoisomerase I), anti-centromere antibody (CREST syndrome), anti-nuclear antibody (ANA), anti-RNA polymerase III antibody, anti-U1-RNP antibody.
Laboratory Findings
Laboratory findings consistent with the diagnosis of scleroderma include:[1]
- Anti-Scl-70 antibody (Topoisomerase I)
- Anti-centromere antibody (CREST syndrome)[2]
- Anti-nuclear antibody (ANA)
- Anti-RNA polymerase III antibody
- Anti-U1-RNP antibody
References
- ↑ Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (June 1980). "Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome". Arthritis Rheum. 23 (6): 617–25. PMID 6155920.
- ↑ Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL (October 1984). "The anticentromere antibody: disease specificity and clinical significance". Mayo Clin. Proc. 59 (10): 700–6. PMID 6384675.